CCL5 and glioblastoma: designed a CCL5 peptide and NO donor conjugate of a furoxans–gemcitabine (NG)‐modified bioinspired lipoprotein system (C‐LNG), in which the CCL5 peptide was used to target the GBM site and NG was used as a radiosensitizer to inhibit DNA repair activity.[138] C‐LNG was found to preferentially target GBM tumor sites and significantly inhibit tumor growth in two orthotopic GBM tumor models.